Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.
复制标题
DOI：
10.1517/17425255.1.3.473
复制
发表时间：
2005-10-01
影响因子：
4.3
通讯作者：
Morse, Gene D
中科院分区：
文献类型：
--
作者：
Ma, Qing;Okusanya, Olanrewaju O;Morse, Gene D
非核苷逆转录酶抑制剂 (NNRTI) 是一组抑制 HIV 1 型逆转录酶的多种化合物。尽管具有共同的作用机制，但已批准的 NNRTIs（地拉韦啶、依非韦伦和奈韦拉平）在结构和药代动力学特征上有所不同。每种 NNRTI 都会通过细胞色素 P450 (CYP) 酶系统进行生物转化，因此在与其他抗逆转录病毒药物联合使用时，易于产生具有临床意义的药物相互作用。此外，它们还与其他并发药物和补充/替代药物相互作用，充当药物代谢 CYP 酶的诱导剂或抑制剂。根据当前指南的建议，在设计联合用药方案时，这些药物相互作用成为临床使用这些药物时的重要考虑因素。本综述提供了 NNRTI 药代动力学相互作用的最新总结。
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a diverse group of compounds that inhibit HIV Type 1 reverse transcriptase. Although possessing a common mechanism of action, the approved NNRTIs, delavirdine, efavirenz and nevirapine, differ in structural and pharmacokinetic characteristics. Each of the NNRTIs undergoes biotransformation by the cytochrome P450 (CYP) enzyme system, thus making them prone to clinically significant drug interactions when combined with other antiretrovirals. In addition, they interact with other concurrent medications and complementary/alternative medicines, acting as either inducers or inhibitors of drug-metabolising CYP enzymes. These drug interactions become an important consideration in the clinical use of these agents when designing combination regimens, as recommended by current guidelines. This review provides an updated summary of pharmacokinetic interactions with NNRTIs.